Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Turn Therapeutics Inc.NASDAQ: TTRX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization of $14.45K in Q1 FY2026
Q1 FY2026 depreciation & amortization was $14.45K. Trailing-twelve-month depreciation & amortization was $42.29K.
Context
- Depreciation & amortization increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $14.45K or moves back toward the trailing-twelve-month quarterly average of $10.57K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 52.75K USD
- Year-over-year change
- +11.1%
- 2-year CAGR
- +9.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.75K | +11.1% |
| FY2024 | 2024-12-31 | 47.48K | +8.1% |
| FY2023 | 2023-12-31 | 43.92K | — |
Depreciation & Amortization vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's LTM Mar 2026 depreciation & amortization of $42.29K is the 7th highest of the 9 companies compared; the peer median is $66.84K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.38M | -44.0% | +12.9% | 6.0% | |
| LTM Mar 2026 | $6.03M | -3.9% | +1.1% | 40.1% | |
| LTM Mar 2026 | $251K | -0.8% | -1.0% | — | |
| LTM Mar 2026 | $80.68K | +3.8% | +5.9% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +241.9% | +136.6% | 0.4% |
| LTM Mar 2026 | $47.85K | +47.9% | +108.0% | — | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | $42.29K | — | — | — |
| LTM Apr 2026 | $28K | -6.7% | -5.0% | — | |
| LTM Mar 2026 | $876 | -75.7% | -21.0% | — | |
| Peer median (excluding TTRX) | $66.84K | -2.4% | +3.5% | 6.0% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin | — | — | — |
| Research & Development | 7.5K | 245.96K | 265.57K |
| Selling, General & Admin | 2.3M | 1.55M | 5.59M |
| Operating Expenses | 2.31M | 1.8M | 5.86M |
| Depreciation & Amortization | 43.92K | 47.48K | 52.75K |
| EBITDA | (2.25M) | (1.72M) | (3.14M) |
| EBITDA Margin | — | — | — |
| Operating Income | (2.31M) | (1.8M) | (5.86M) |
| Operating Margin | — | — | — |
| Interest Income | 15.88K | 28.71K | 29.58K |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 15.88K | 28.71K | 2.66M |
| Income Before Tax | (2.29M) | (1.77M) | (3.19M) |
| Pre-Tax Margin | — | — | — |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (2.29M) | (1.77M) | (3.19M) |
| Net Margin | — | — | — |
| EPS (Basic) | (0.17) | (0.13) | (0.23) |
| EPS (Diluted) | (0.17) | (0.13) | (0.23) |
| Weighted Avg Shares | 13.25M | 13.42M | 13.74M |
| Weighted Avg Shares (Diluted) | 13.25M | 13.42M | 13.74M |
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.